Organization
University of Southern California Marshall School of Business
37 abstracts
Abstract
An analysis of the trends and distribution of political contributions from hematologists and oncologists in the United States.Org: University of Southern California Marshall School of Business,
Abstract
A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors.Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea, Division of Oncology, Rambam health care, Haifa, Israel,
Abstract
Comparative effectiveness of NALIRIFOX vs. FOLFIRINOX in pancreatic cancer.Org: University of Southern California Marshall School of Business, Medical Oncology and Therapeutics, City of Hope/AccessHope,
Abstract
Efficacy from the phase 1 study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with head and neck squamous cell carcinoma.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Fulgent Pharma,
Abstract
AI-assisted colonoscopy in gastroenterology fellowship training: An interim analysis of a randomized controlled trial.Org: University of Southern California Marshall School of Business,
Abstract
Real-world impact of KRAS mutations on clinical outcomes in metastatic colorectal cancer treated with trifluridine-tipiracil in the USA.Org: Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, Caris Life Sciences, Irving, TX, Irving, TX, San Diego, CA,
Abstract
Utilization of TAS-102 (TAS) or regorefenib (Rego) among commercially insured refractory metastatic colorectal cancer (R-mCRC) patients.Org: University of Southern California Marshall School of Business, Medical Oncology and Therapeutics, City of Hope/AccessHope,
Abstract
Impact of GABA pathway genes expression on first-line treatment outcomes in patients (pts) with metastatic colorectal cancer (mCRC): Data from CALGB/SWOG 80405 (Alliance).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Department of Population and Public Health Sciences, University of Wisconsin Carbone Cancer Center,
Abstract
Attitudes and engagement about cascade genetic testing in a population-based cohort of women diagnosed with cancer.Org: University of Michigan, Emory University, Atlanta, GA, USA, University of Southern California Marshall School of Business, Stanford Cancer Institute, Stanford University School of Medicine,
Abstract
Molecular characterization of NUT carcinoma: A report from the NUT carcinoma registry.Org: Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY, Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
Time to target TIM-3 in colorectal cancer: TIM-3 expression to predict survival outcomes in patients in CALGB (Alliance)/SWOG 80405.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Los Angeles Medical Center, Keck School of Medicine of the University of Southern California, Department of Population and Public Health Sciences,
Abstract
Survival and mutational differences based on ESR1 and ESR2 expression in non-small cell lung cancer (NSCLC).Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, University of California, Irvine Medical Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, SongDang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Abstract
Characteristics and outcomes of plasmablastic lymphoma in a predominantly Hispanic population.Org: Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
Final results from phase I study of PSCA-targeted chimeric antigen receptor (CAR) T cells in patients with metastatic castration resistant prostate cancer (mCRPC).Org: City of Hope Comprehensive Cancer Center, City of Hope National Medical Center, City of Hope Beckman Research Institute, USC Norris Comprehensive Cancer Center, University of Southern California Marshall School of Business,
Abstract
EphrinB2 (B2) expression predicts poor response to PD1/L1 antibodies (Ab) in metastatic urothelial carcinoma (mUC).Org: University of Southern California Marshall School of Business, Vasgene Therapeutics, Inc, Rutgers University, Dana-Farber Cancer Institute, University of Colorado Cancer Center Anschutz Medical Campus,
Abstract
Comparison of next-generation sequencing and flow cytometry in detecting minimal residual disease in adult acute lymphoid leukemia: Evaluating clinical outcomes in a single-center study.Org: University of Southern California Marshall School of Business, Norris Comprehensive Cancer Center, Los Angeles, CA,
Abstract
Initial results of dose finding in a first-in-human phase 1 study of a novel Claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23 in patients with advanced solid tumors.Org: University of California Los Angeles Medical Center, Mayo Clinic, University of Minnesota Masonic Cancer Center, Minneapolis, MN, Vanadro LLC, University of Southern California Marshall School of Business,
Abstract
A phase 2 study (DisTinGuish) of DKN-01 in combination with tislelizumab + chemotherapy as first-line (1L) therapy in patients with advanced gastric or GEJ adenocarcinoma (GEA).Org: Mass General Cancer Center, Mayo Clinic, University of California Irvine, Duke University Medical Center, The Angeles Clinic & Research Institute, A Cedars-Sinai Affiliate, Los Angeles, CA,
Abstract
The differential response to immune checkpoint inhibitors (ICIs) according to mismatch repair alterations in gastrointestinal (GI) non-colorectal cancers (non-CRCs) and the impact of dual vs. monotherapy ICIs on survival in GI (CRC and non-CRC) cancers.Org: Caris Life Sciences, Irving, TX, Fox Chase Cancer Center, Barbara Ann Karmanos Cancer Institute, Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center,
Abstract
A phase 1 dose escalation/expansion study of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.Org: University of Southern California Marshall School of Business, Norris Comprehensive Cancer Center, Fulgent Therapeutics, ANP Technologies, Inc,
Abstract
Harnessing the power of tumor-infiltrating lymphocytes: A first-in-human study of GT201 as monotherapy in advanced solid tumors.Org: Grit Biotechnology, The Affiliated Hospital of XuZhou Medical University, Xuzhou, China, The First Affiliated Hospital of Soochow University, Grit Biotechnology Co. Ltd, University of Southern California Marshall School of Business,
Abstract
FOXC1 expression in meningiomas.Org: Nationwide Children’s Hospital, Caris Life Sciences, Irving, TX, Fox Chase Cancer Center, Temple University Hospital, Philadelphia, PA, Miami Cancer Institute - Baptist Health South Florida,
Abstract
Genomic landscapes to characterize mismatch-repair deficiency (dMMR)/microsatellite instability-high (MSI-H) gastrointestinal (GI) cancers stratified by tumor mutation burden (TMB).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, Department of Preventive Medicine,
Abstract
Comprehensive profiling of clock genes expression in hepatocellular carcinoma (HCC).Org: Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, University of Southern California Marshall School of Business, Caris Life Sciences, Irving, TX, Lawrence J. Ellison Institute for Transformative Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA,
Abstract
Genetic ancestry associations with somatic mutations in a real-world cohort of over 3,000 patients with prostate cancer.Org: Tempus Labs, Inc., Tempus AI, University of Southern California Marshall School of Business,
Abstract
Association of adaptive immunity/inflammatory genes with survival in prostate cancer.Org: Caris Life Sciences, Irving, TX, Barbara Ann Karmanos Cancer Institute, University of California San Diego, University of Southern California Marshall School of Business, University of Minnesota Masonic Cancer Center, Minneapolis, MN,
Abstract
Subsets of interferon signaling and response to immune checkpoint blockade.Org: Yale School of Medicine, University of Southern California Marshall School of Business, Yale University School of Public Health,
Abstract
Exchanging genomics reports between pathology labs and medical centers using the Minimal Clinical Oncology Data Element (mCODE) FHIR implementation guide.Org: MITRE, Tempus Labs, Inc., University of Southern California Marshall School of Business,
Abstract
Association between targeted cancer drug net health benefit and uptake, patient out-of-pocket spending, and total spending.Org: Massachusetts General Hospital, Perelman School of Medicine, University of Pennsylvania, University of Southern California Marshall School of Business,
Abstract
Investigating the novel CD16A and epidermal growth factor receptor (EGFR) bispecific innate cell engager, AFM24, to leverage the innate immune system: Interim results from the colorectal cancer (CRC) cohort.Org: INCLIVA-Biomedical Research Institute, Biomedical Research Institute INCLIVA, Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, University of Valencia, Affimed Inc.,
Abstract
The influence of grade on mortality risk in salivary gland malignancy.Org: Cedars-Sinai Medical Center, Cedars-Sinai Medical Center Medical Genetics Prenatal Diagnosis Center, Cedars Sinai Medical Center, University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
Absolute lymphocyte counts (ALC) recovery and risk of viral reactivation in the setting of haploidentical hematopoietic stem cell transplant.Org: University of Southern California Marshall School of Business, Norris Comprehensive Cancer Center,
Abstract
From abstract to publication: Factors predictive of publication success in the field of breast and gynecological malignancy.Org: Roswell Park Comprehensive Cancer Center, Hamdard Institute of Medical Sciences and Research, New Delhi, India, Rochester General Hospital, Westchester Medical Center, Shree Guru Gobind Singh Tricenterary University,
Abstract
Real world prognostic utility of body mass index and platelet lymphocyte ratio in first-line immunotherapy response in stage IV non-small cell lung cancer.Org: University of Southern California Marshall School of Business, Norris Comprehensive Cancer Center, California University of Science and Medicine, Division of Oncology, USC Keck School of Medicine,
Abstract
“EFFECTIVE LUNG AGE” IN SUBJECTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSc-ILD) IN THE SENSCIS TRIALOrg: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharma GmbH & Co. KG, University of Montpellier, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), University Hospital Zurich,
Abstract
ANAKINRA STEP-DOWN THERAPY IN ADULT-ONSET STILL'S DISEASEOrg: University of Southern California Marshall School of Business,
Abstract
Association of renal dysfunction and development of tophi in subjects with chronic refractory gout and response to treatment with pegloticaseOrg: University of Florida Department of Health Outcomes and Biomedical Informatics, University of Alabama at Birmingham Department of Hematology, Birmingham, AL, University of Southern California Marshall School of Business, Horizon Pharma USA, AMPEL BioSolutions LLC,